Admedus will present CardioCel data for the complete repair of aortic heart valves at the 29th European Association for Cardio-Thoracic Surgery Annual Meeting (EACTS) (3–7 October, Amsterdam, the Netherlands).
The CardioCel session titled “AVR: What is new?”, will take place at EACTS on Monday, 5 October and will provide the full results of a pre-clinical trial undertaken by heart surgeon and lead researcher professor Bart Meuris at KU Leuven University, Belgium.
“This study represents a world first tri-leaflet aortic valve repair in this animal model, and as a surgeon the results have been very exciting. I look forward to presenting the full findings at EACTS in October,” said Meuris.
The data presented at the EACTS conference will support the hundreds of patients that have already had their heart valve repaired with CardioCel.
“Demonstrating CardioCel’s success in this world first heart valve repair study is a key step for the company, as we continue to develop personalised medical solutions with large market applications,” said Admedus chief executive officer, Lee Rodne.
“We are looking to address aortic stenosis, or narrowing, which is the most common valvular heart disease in developed countries. Traditionally aortic valves have been replaced with a bio-prosthetic or mechanical heart valve rather than being surgically repaired, as surgeons have not had a tissue that can withstand such a high pressured area within the heart until now. CardioCel has been proven to have the tensile strength to work in a pressured environment, as well as having the added benefit of not calcifying like other tissues, and instead actively facilitates host tissue regeneration. This is a huge advantage for patients, as it means they can avoid the need to have repeat surgeries later in life.”
In addition to the presentation, Admedus will be hosting a “21st Century Innovators Dinner Meeting” at EACTS on Monday, 5 October at featuring key opinion leaders Meuris and Domenico Mazzitelli from Munich, Germany.
Admedus will be undertaking a CardioCel tri-leaflet aortic valve repair clinical study, which is expected to be initiated shortly at key global heart centres. This study is designed to further show the utility of CardioCel in repairing aortic heart valves and its potential for improved patient outcomes compared to bio-prosthetic valves which may need to be replaced multiple times throughout a patient’s life.
